Methods involving long lasting synthetic exendin-4-peptide conjugates

• US 8,084,414 B2
• Filed: 08/30/2005
• Issued: 12/27/2011
• Est. Priority Date: 05/17/1999
• Status: Expired due to Fees

• Current Assignee: ConjuChem LLC (Colabor Group, Inc.)
• Original Assignee: ConjuChem LLC (Colabor Group, Inc.)
• Inventors: Bridon, Dominique P., L'Archeveque, Benoit, Holmes, Darren L., Leblanc, Anouk, St. Pierre, Serge
• Primary Examiner(s): CHEN, STACY BROWN
• Application Number:
  US11/215,967
• Publication Number:
  US 20060058235A1
• Time in Patent Office: 2,310 Days
• Field of Search: None
• US Class Current: 514/1.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/643 Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 14/57563 Vasoactive intestinal peptide [VIP]; Related peptides
• CPC Class Codes: C07K 14/605 Glucagons
• CPC Class Codes: C12N 2740/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.

Claims

1. A method for treating diabetes in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to the following formula:

2. The method of claim 1, wherein said compound is in association with a physiologically acceptable medium.

17. The method of any one of claims 1-8, wherein the diabetes is Type II diabetes.

18. The method of claim 1, 3, 9, 11 or 12, wherein the subject is a human.

19. The method of claim 17 wherein the subject is a human.

3. A method for treating diabetes in a subject, comprising administering to the subject a therapeutically effective amount of a conjugate formed by reacting a compound according to the following formula:

4. The method of claim 3, wherein said albumin is serum albumin.

5. The method of claim 3, wherein said reacting occurs between said compound and cysteine 34 thiol of albumin.

6. The method of claim 3, wherein said conjugate is in association with a physiologically acceptable medium.

7. The method of claim 4, wherein said conjugate is in association with a physiologically acceptable medium.

8. The method of claim 5, wherein said conjugate is in association with a physiologically acceptable medium.

20. The method of claim 4, wherein said serum albumin is human serum albumin.

21. The method of claim 5, wherein said albumin is serum albumin.

22. The method of claim 21, wherein said conjugate is in association with a physiologically acceptable medium.

23. The method of claim 22, wherein the subject is a human.

24. The method of claim 23, wherein the diabetes is Type II diabetes.

25. The method of claim 5, wherein said albumin is human serum albumin.

26. The method of claim 25, wherein said conjugate is in association with a physiologically acceptable medium.

27. The method of claim 26, wherein the subject is a human.

28. The method of claim 27, wherein the diabetes is Type II diabetes.

9. A method for enhancing the expression of insulin in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to the following formula:

10. The method of claim 9, wherein said compound is in association with a physiologically acceptable medium.

11. A method for enhancing the expression of insulin in a subject, comprising administering to the subject a therapeutically effective amount of a conjugate formed by reacting a compound according to the following formula:

12. The method of claim 11, wherein said albumin is serum albumin.

13. The method of claim 11, wherein said reacting occurs between said compound and cysteine 34 thiol of albumin.

14. The method of claim 11, wherein said conjugate is in association with a physiologically acceptable medium.

15. The method of claim 12, wherein said conjugate is in association with a physiologically acceptable medium.

16. The method of claim 13, wherein said conjugate is in association with a physiologically acceptable medium.

29. The method of claim 12, wherein said serum albumin is human serum albumin.

30. The method of claim 13, wherein said albumin is serum albumin.

31. The method of claim 30, wherein said conjugate is in association with a physiologically acceptable medium.

32. The method of claim 31, wherein the subject is a human.

33. The method of claim 32, wherein the subject has Type II diabetes.

34. The method of claim 13, wherein said albumin is human serum albumin.

35. The method of claim 34, wherein said conjugate is in association with a physiologically acceptable medium.

36. The method of claim 35, wherein the subject is a human.

37. The method of claim 36, wherein the subject has Type II diabetes.